© 2021 MJH Life Sciences and Gene Therapy Live. All rights reserved.
© 2021 MJH Life Sciences™ and Gene Therapy Live. All rights reserved.
July 26, 2021
Heterogeneity in the cellular and molecular features of CAR T-cell products contributes to variation in efficacy and toxicity follow treatment with axicabtagene ciloleucel.
June 21, 2021
C. Ola Landgren, MD, PhD, discussed the role of CAR T-cell therapies in multiple myeloma.
June 20, 2021
James Hoffman, MD, discussed the significance of the approval of ide-cel for patients with multiple myeloma.
May 13, 2021
UCARTCS1A is the first allogeneic CAR T-cell product developed to target CS1 and SLAMF7, both of which are highly and consistently expressed in multiple myeloma.